Best response for lesions at 1.5 to 6 months after VLDRT
| Best response . | Overall (N = 227) . | Intent of VLDRT . | Lesion histology . | Nodal description . | Site description . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Non-curable (n = 181) . | Potentially curable (n = 46) . | FL (n = 144) . | MZL (n = 65) . | Low-grade indolent (n = 18) . | Nodal (n = 90) . | Extranodal or both (n = 137) . | Cutaneous (n = 41) . | Non-skin (n = 186) . | ||
| CR | 154 (68) | 117 (65) | 37 (80) | 95 (66) | 47 (72) | 12 (67) | 56 (62) | 98 (72) | 35 (85) | 119 (64) |
| PR | 49 (22) | 42 (23) | 7 (15) | 34 (24) | 11 (17) | 4 (22) | 20 (22) | 29 (21) | 5 (12) | 44 (24) |
| SD | 13 (5.7) | 11 (6.1) | 2 (4.3) | 8 (5.6) | 4 (6.2) | 1 (5.6) | 7 (7.8) | 6 (4.4) | 1 (2.4) | 12 (6.5) |
| PD | 11 (4.8) | 11 (6.1) | 0 (0) | 7 (4.9) | 3 (4.6) | 1 (5.6) | 7 (7.8) | 4 (2.9) | 0 (0) | 11 (5.9) |
| Best response . | Overall (N = 227) . | Intent of VLDRT . | Lesion histology . | Nodal description . | Site description . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Non-curable (n = 181) . | Potentially curable (n = 46) . | FL (n = 144) . | MZL (n = 65) . | Low-grade indolent (n = 18) . | Nodal (n = 90) . | Extranodal or both (n = 137) . | Cutaneous (n = 41) . | Non-skin (n = 186) . | ||
| CR | 154 (68) | 117 (65) | 37 (80) | 95 (66) | 47 (72) | 12 (67) | 56 (62) | 98 (72) | 35 (85) | 119 (64) |
| PR | 49 (22) | 42 (23) | 7 (15) | 34 (24) | 11 (17) | 4 (22) | 20 (22) | 29 (21) | 5 (12) | 44 (24) |
| SD | 13 (5.7) | 11 (6.1) | 2 (4.3) | 8 (5.6) | 4 (6.2) | 1 (5.6) | 7 (7.8) | 6 (4.4) | 1 (2.4) | 12 (6.5) |
| PD | 11 (4.8) | 11 (6.1) | 0 (0) | 7 (4.9) | 3 (4.6) | 1 (5.6) | 7 (7.8) | 4 (2.9) | 0 (0) | 11 (5.9) |
Data are n (%).
PD, progressive disease; SD, stable disease.